TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T51115	Voltage-gated calcium channel alpha Cav1.2	D03FLC	Lamotrigine	Approved	3878	C9H7Cl2N5	256.089	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	IC50 = 1258925.41 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D03IGH	Darunavir	Approved	213039	C27H37N3O7S	547.7	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	IC50 = 1584893.19 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D04FVU	Palonosetron	Approved	6337614	C19H24N2O	296.4	C1C[C@@H]2CN(C(=O)C3=CC=CC(=C23)C1)[C@@H]4CN5CCC4CC5	IC50 = 398107.17 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D04VMT	Sotalol	Approved	5253	C12H20N2O3S	272.37	CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O	IC50 = 1023000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D05MQK	Tadalafil	Approved	110635	C22H19N3O4	389.4	CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36	IC50 = 398107.17 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D08CDI	Lapatinib	Approved	208908	C29H26ClFN4O4S	581.1	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	IC50 = 1995262.31 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0B3UJ	Paliperidone	Approved	115237	C23H27FN4O3	426.5	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	IC50 = 398107.17 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0C9SY	Vardenafil	Approved	135400189	C23H32N6O4S	488.6	.	IC50 = 251188.64 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0D8VE	Halothane	Approved	3562	C2HBrClF3	197.38	C(C(F)(F)F)(Cl)Br	IC50 = 1800000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0E6XR	Dasatinib	Approved	3062316	C22H26ClN7O2S	488	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	IC50 = 251188.64 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0Q5UQ	Exjade	Approved	214348	C21H15N3O4	373.4	.	IC50 = 1000000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0U0VU	SILODOSIN	Approved	5312125	C25H32F3N3O4	495.5	C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F	IC50 = 794328.23 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0U2JP	Sitagliptin	Approved	4369359	C16H15F6N5O	407.31	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	IC50 = 100000000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0X5ZI	Ambrisentan	Approved	6918493	C22H22N2O4	378.4	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	IC50 = 2511886.43 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0Y5AM	Darifenacin	Approved	444031	C28H30N2O2	426.5	C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5	IC50 = 1584893.19 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	BMWG84	6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]-	Investigative	46206000	C23H26FN7O3	467.5	C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5	IC50 > 333000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	BVJH09	1-[(2S)-2-Amino-2-[(1r,4S)-4-[({3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}methyl)amino]cyclohexyl]ethyl]-7-methoxy-1,2-dihydro-1,5-naphthyridin-2-one	Investigative	46205341	C25H30N6O4	478.5	COC1=CC2=C(C=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N)N=C1	IC50 > 333000 nM	Non binder
T51115	Voltage-gated calcium channel alpha Cav1.2	D0R6MT	isobutylmethylxanthine	Investigative	3758	C10H14N4O2	222.24	CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2	IC50 = 466000 nM	Non binder